Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma. / Dimopoulos, Konstantinos; Fibiger Munch-Petersen, Helga; Winther Eskelund, Christian; Sjö, Lene Dissing; Ralfkiær, Elisabeth; Gimsing, Peter; Grønbæk, Kirsten.

In: Leukemia and Lymphoma, Vol. 60, No. 1, 2019, p. 180-188.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Dimopoulos, K, Fibiger Munch-Petersen, H, Winther Eskelund, C, Sjö, LD, Ralfkiær, E, Gimsing, P & Grønbæk, K 2019, 'Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma', Leukemia and Lymphoma, vol. 60, no. 1, pp. 180-188. https://doi.org/10.1080/10428194.2018.1466290

APA

Dimopoulos, K., Fibiger Munch-Petersen, H., Winther Eskelund, C., Sjö, L. D., Ralfkiær, E., Gimsing, P., & Grønbæk, K. (2019). Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma. Leukemia and Lymphoma, 60(1), 180-188. https://doi.org/10.1080/10428194.2018.1466290

Vancouver

Dimopoulos K, Fibiger Munch-Petersen H, Winther Eskelund C, Sjö LD, Ralfkiær E, Gimsing P et al. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma. Leukemia and Lymphoma. 2019;60(1):180-188. https://doi.org/10.1080/10428194.2018.1466290

Author

Dimopoulos, Konstantinos ; Fibiger Munch-Petersen, Helga ; Winther Eskelund, Christian ; Sjö, Lene Dissing ; Ralfkiær, Elisabeth ; Gimsing, Peter ; Grønbæk, Kirsten. / Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma. In: Leukemia and Lymphoma. 2019 ; Vol. 60, No. 1. pp. 180-188.

Bibtex

@article{bd064e8e30d846c78411d17a1fa38c10,
title = "Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma",
abstract = "The immunomodulatory drug thalidomide, and its analogs, lenalidomide, and pomalidomide (IMiDs), have become essential components of the standard treatment for multiple myeloma (MM), and have led to significant improvement of survival in patients with this devastating disease. Cereblon (CRBN), the direct target of IMiDs, has been proposed as a predictive biomarker of response to IMiDs. Using standard immunohistochemistry in formalin-fixed paraffin embedded (FFPE) bone marrow samples of 23 patients treated with a lenalidomide-containing regimen, we found that the malignant plasma cells of all the patients stained positive for CRBN, IKZF1, and IKZF3, regardless of sensitivity to IMiDs. Moreover, we detected no mutations in CRBN, IKZF1, IKZF3, CUL4A, or IRF4, but found expanded TP53-mutated clones in two out of seven sequential samples. Thus, our data argue against the use of CRBN and its downstream targets as predictive biomarkers of IMiD response in MM and confirm clonal evolution patterns during lenalidomide resistance.",
author = "Konstantinos Dimopoulos and {Fibiger Munch-Petersen}, Helga and {Winther Eskelund}, Christian and Sj{\"o}, {Lene Dissing} and Elisabeth Ralfki{\ae}r and Peter Gimsing and Kirsten Gr{\o}nb{\ae}k",
year = "2019",
doi = "10.1080/10428194.2018.1466290",
language = "English",
volume = "60",
pages = "180--188",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor & Francis",
number = "1",

}

RIS

TY - JOUR

T1 - Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma

AU - Dimopoulos, Konstantinos

AU - Fibiger Munch-Petersen, Helga

AU - Winther Eskelund, Christian

AU - Sjö, Lene Dissing

AU - Ralfkiær, Elisabeth

AU - Gimsing, Peter

AU - Grønbæk, Kirsten

PY - 2019

Y1 - 2019

N2 - The immunomodulatory drug thalidomide, and its analogs, lenalidomide, and pomalidomide (IMiDs), have become essential components of the standard treatment for multiple myeloma (MM), and have led to significant improvement of survival in patients with this devastating disease. Cereblon (CRBN), the direct target of IMiDs, has been proposed as a predictive biomarker of response to IMiDs. Using standard immunohistochemistry in formalin-fixed paraffin embedded (FFPE) bone marrow samples of 23 patients treated with a lenalidomide-containing regimen, we found that the malignant plasma cells of all the patients stained positive for CRBN, IKZF1, and IKZF3, regardless of sensitivity to IMiDs. Moreover, we detected no mutations in CRBN, IKZF1, IKZF3, CUL4A, or IRF4, but found expanded TP53-mutated clones in two out of seven sequential samples. Thus, our data argue against the use of CRBN and its downstream targets as predictive biomarkers of IMiD response in MM and confirm clonal evolution patterns during lenalidomide resistance.

AB - The immunomodulatory drug thalidomide, and its analogs, lenalidomide, and pomalidomide (IMiDs), have become essential components of the standard treatment for multiple myeloma (MM), and have led to significant improvement of survival in patients with this devastating disease. Cereblon (CRBN), the direct target of IMiDs, has been proposed as a predictive biomarker of response to IMiDs. Using standard immunohistochemistry in formalin-fixed paraffin embedded (FFPE) bone marrow samples of 23 patients treated with a lenalidomide-containing regimen, we found that the malignant plasma cells of all the patients stained positive for CRBN, IKZF1, and IKZF3, regardless of sensitivity to IMiDs. Moreover, we detected no mutations in CRBN, IKZF1, IKZF3, CUL4A, or IRF4, but found expanded TP53-mutated clones in two out of seven sequential samples. Thus, our data argue against the use of CRBN and its downstream targets as predictive biomarkers of IMiD response in MM and confirm clonal evolution patterns during lenalidomide resistance.

U2 - 10.1080/10428194.2018.1466290

DO - 10.1080/10428194.2018.1466290

M3 - Journal article

C2 - 29718735

VL - 60

SP - 180

EP - 188

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1

ER -

ID: 212463569